Fig. 6: H3-nanovax formulations reduce viral load against homologous and heterosubtypic infection. | npj Vaccines

Fig. 6: H3-nanovax formulations reduce viral load against homologous and heterosubtypic infection.

From: Polyanhydride nanovaccine against H3N2 influenza A virus generates mucosal resident and systemic immunity promoting protection

Fig. 6

C57BL/6 mice were vaccinated (H3-nanovax (HA/NP; Pink), (NA/NP; Blue), (NA/M1; Purple), or left unvaccinated (naïve)) as described in Fig. 2. 32 days following prime vaccination, mice were infected with 390 TCIU IAV A/Hong Kong/1/68 (a) or 1108 TCIU A/Puerto Rico/8/34 (b). At 3 days post infection, lungs were harvested and mechanically homogenized. TCID50/mL was measured in triplicate for each mouse. Error bars, mean ± s.e.m. LOD (dotted line) = Limit of Detection. Data representative of one (n = 3 mice/group) independent experiment *P < 0.05, ***P < 0.001, ****P < 0.0001, (One-way ANOVA with Tukey’s multiple comparisons test on log transformed data).

Back to article page